November 7, 2019 11:10 AM EST
R&D

De­clar­ing topline PhI­II win, Take­da re­vives block­buster hopes for its trou­bled mul­ti­ple myelo­ma drug

Jason Mast

Editor

Five months af­ter dis­mal tri­al re­sults con­vinced Take­da to scrap an en­tire Phase III pro­gram for their mul­ti­ple myelo­ma drug Nin­laro, the Japan­ese gi­ant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times